Company News
Glenmark Launches Lacosamide Injection in US Market
Glenmark Pharmaceuticals launches Lacosamide Injection USP, a generic equivalent to UCB's Vimpat® Injection.
The US market for Vimpat® Injection achieved annual sales of approximately $15.2 million fo
